NCT05091541View on ClinicalTrials.gov

A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

125

Participants

Timeline

Start Date

October 20, 2021

Primary Completion Date

October 20, 2024

Study Completion Date

October 20, 2039

Conditions

B-cell Non-Hodgkin's Lymphoma

Interventions

DRUG

Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection

CT120 is an autologous CD19/22 targeted CAR-T cells injection. The dosage form is a cryopreserved injection solution. The T cells aphesis from subjects then been manufactured to express CAR to binding CD19 and CD22 on B-cell lymphoma.

All Listed Sponsors

lead

Nanjing IASO Biotechnology Co., Ltd.

INDUSTRY

NCT05091541 - A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter